Cancer immunotherapy is a transformative treatment approach that activates or enhances the body’s immune system to identify and destroy cancer cells. Unlike traditional therapies that target the tumor directly, immunotherapy works by stimulating immune responses or reversing immune evasion mechanisms. Key modalities include immune checkpoint inhibitors, CAR-T cell therapy, cancer vaccines, monoclonal antibodies, and oncolytic viruses.

These strategies have shown remarkable success in cancers such as melanoma, lung cancer, and hematological malignancies, offering durable responses even in advanced stages. However, not all patients respond equally, highlighting the importance of predictive biomarkers, tumor mutational burden, and the tumor microenvironment. Ongoing research aims to overcome resistance, reduce immune-related adverse effects, and develop combination regimens with chemotherapy, radiation, or targeted agents. Immunotherapy represents a paradigm shift in oncology, with a growing focus on tailoring immune-based treatments to individual tumor profiles.

The Journal of Cancer Biology and Treatment, we prioritize innovative studies on immunotherapeutic mechanisms, clinical applications, immune biomarkers, and combination strategies. Submissions addressing real-world efficacy, immune landscape profiling, and emerging immune-based technologies are particularly welcome, as we seek to advance the next generation of cancer immunotherapy that is both precise and accessible.